Exhibit 10.1

				7555 Innovation Way Mason, OH 45040 United States 513-755-4100

August 4, 2020

Angela Wirick

Dear Angie,

I am pleased to formally extend this offer to you for your promotion to the position of Chief Financial Officer. This letter will confirm the details of the offer. This formal offer will remain open until the close of business on August 6, 2020.

Position and Reporting Responsibilities:

Chief Financial Officer, reporting to Michael Carrel, President & Chief Executive Officer

Effective Date:

Your tentative start date is set to August 6, 2020.

Compensation:

Your base salary will be $16,041.67 semi-monthly, which annualizes to $385,000, and is subject to deductions for taxes and other withholdings as required by law. This is an exempt position which means you are not eligible to receive overtime.

In addition, you will continue to participate in the company’s annual Corporate Incentive Plan (CIP) with a target potential of 50% of your base salary, prorated based on your start date (see above). CIP payouts are expected to be made to qualifying employees in cash on a lump sum basis on or about March 15th following the end of the CIP year. You must be an active employee at the date of CIP payout to be eligible to receive a CIP bonus.

AtriCure Equity:

You shall be issued two separate equity grants totaling $2,250,000 in value pursuant to AtriCure’s Amended and Restated 2014 Stock Incentive Plan (2014 Plan). The first grant will be made effective as of your promotion start date (see above) and will consist of an award of restricted shares (RSAs) of common stock valued at $1,500,000. The number of restricted shares granted shall be based on the Nasdaq market closing price on the grant date. The RSAs shall vest over three years at a rate of 33.3% per year on the anniversary of the grant date, subject to the terms and conditions of our standard RSA agreement and the 2014 Plan.

The second grant will be made effective on or about March 1, 2021 (or such other similar date per our standard annual equity grant cycle) and will consist of an award of performance shares (PSAs) valued at $750,000. The PSAs shall “cliff” vest after the end of a three-year performance measurement period, subject to the terms and conditions of our standard PSA agreement, including the satisfaction of the performance goals therein, and the 2014 Plan.

At-Will Status:

This employment offer is not a guarantee of continued employment or any term, privilege or condition of employment. Neither you nor AtriCure are bound to continue the relationship established hereunder.

Acceptance Procedure:

To accept this offer, please sign below and return the signed offer letter to Tonya Austin.

We look forward to the contributions you will continue to make at AtriCure and to the professional and personal opportunities we will be able to provide to you!

				7555 Innovation Way Mason, OH 45040 United States 513-755-4100

Should you have any questions regarding this offer, please feel free to contact me at 612-839-2902.

Sincerely yours,

Michael H. Carrel

President and Chief Executive Officer

AtriCure, Inc.

CC: Tonya Austin

I, Angela Wirick, have read and understand the terms and conditions of this offer made by AtriCure. My signature below represents that the terms and conditions are acceptable to me. I also understand that my employment with AtriCure is at-will employment and that I may at any time terminate my employment with the company with or without notice. I also understand that AtriCure, Inc. may at any time terminate their employment relationship with me with or without notice. I further understand that any company benefits and compensation plans offered to me during my employment are subject to change and may change at any time at the company’s discretion.

Agreed:

Exhibit 99.1

For immediate release

August 6, 2020

AtriCure Announces Angie Wirick as Chief Financial Officer

MASON, Ohio, August 6, 2020 – AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, announced today that Andy Wade is stepping down from the position of Chief Financial Officer (CFO) for personal reasons and moving into an advisory role through March 5, 2021. Angie Wirick, current Vice President of Finance, has been promoted to CFO effective immediately.

“On behalf of our team at AtriCure and our Board of Directors, I want to thank Andy for his contributions to our company over the past 13 years,” said Michael Carrel, President and Chief Executive Officer of AtriCure. “Andy has been instrumental to our global success and position of financial strength. Through his strong leadership, we achieved critical milestones to build AtriCure’s foundation and position our company for accelerated growth. These accomplishments have propelled our company to new levels of success and created significant shareholder value.”

“I am honored to have been a part of a tremendous team and world-class culture at AtriCure,” said Mr. Wade. “It has been a true privilege to work alongside colleagues who are passionately committed to our mission of improving patient lives and to see the growth of our impact in reducing the Afib epidemic around the world. While stepping down was a difficult decision, I am looking forward to moving into an advisory role and spending more time with my family.”

Mr. Carrel also stated, “We are excited to have Angie as our new CFO. Angie has been an integral part of our team for six years. I congratulate Angie on the new role and look forward to continuing to work with her on our strategic initiatives and leading the company into the future.”

Ms. Wirick joined AtriCure in July 2014 and most recently has been the Vice President of Finance, responsible for the global accounting and finance functions of the Company. Before AtriCure, Ms. Wirick spent 12 years at Deloitte & Touche LLP in managerial roles and began her career at Arthur Andersen LLP. Ms. Wirick is a certified public accountant and holds a Bachelor of Science in Accounting from the University of Dayton.

About AtriCure

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator^® Synergy^™ Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip Left Atrial Appendage (LAA) Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure’s cryoICE is the first U.S. Food and Drug Administration (FDA)-cleared cryo ablation probe for the temporary ablation of peripheral nerves to block pain, providing temporary pain relief in cardiac and thoracic procedures. For more information, visit AtriCure.com or follow us on Twitter @AtriCure.

Forward-Looking Statements

This press release contains “forward-looking statements”– that is, statements related to future events that by their nature address matters that are uncertain. For details on the uncertainties that may cause our actual results to be materially different than those expressed in our forward-looking statements, visit http://www.atricure.com/fls as well as our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q which contain risk factors. We do not undertake to update our forward-looking statements. Actual results could differ materially.

CONTACTS:

Lynn Pieper Lewis

Gilmartin Group

Investor Relations

(415) 937-5402

lynn@gilmartinir.com